- Science
- Clinical Trials
- Guide to Clinical Trials Your participation makes a difference
- Clinical Trials in Children Designed to improve kids' health
- Data and Results Sharing our Results
- Integrity and Transparency Building Trust
- Diversity Equity and Representation
- Plain Language Study Results Trial Result Summaries
- Expanded Access & Compassionate Use Possible Treatment Options
- Find a Trial
- Areas of Focus
- Rare Disease Smaller populations but big impact
- Internal Medicine Extending lifespans worldwide
- Inflammation & Immunology Treatment at the molecular level
- Vaccines Preventing the spread of infections
- Oncology The science of optimism
- Anti Infectives Combatting an evolving risk
- Areas of Innovation
- Gene Therapy Breakthroughs become treatments
- Medicinal Sciences The next generation of science
- Precision Medicine Developing tailored medicines
- Maternal Immunization Protecting newborns at the start
- mRNA Technology Unleashing the next wave of scientific innovations
- Diseases & Conditions
- Coronavirus Resources
- Product Pipeline
- Research Sites
- Clinical Trials
- Products
- How Drugs are Made
- Branded vs. Generic Learn the difference
- Biologics & Biosimilars Cures found in nature
- Commitment to Quality Maintaining the highest standards
- Global Supply Strategic manufacturing locations
- Manufacturing Sites Where medicine is made in the U.S.
- Medicine Safety
- Health Literacy Learning to be well
- Treatment Choices Learning about treatment decisions
- Partnering With Patients Helping others by reporting side effects
- Tips for Patients Preventing medication errors
- Reporting Adverse Events
- Counterfeiting Preventing medication errors
- Product Safety
- Product List
- Product Contacts
- PfizerPro for Professionals
- Patient Assistance Programs
- Distributors
- How Drugs are Made
- Stories
- Newsroom
- About
- People
- Executives Our senior-most leadership
- Board Members The people steering our company
- Scientists Our experts making discoveries
- Patient Stories Our patients
- Colleague Stories Our colleagues
- Responsibility
- Ethics & Compliance Each of us is responsible
- Responsible Business Breakthroughs that change patients’ lives
- Patient Advocacy & Engagement Putting Patients First
- Global Impact Meeting urgent needs worldwide
- Diversity, Equity, and Inclusion Everyone has something to offer
- Environmental Sustainability Our responsiblity to the environment
- Human Rights Furthering dignity and worth
- Health & Safety
- Intellectual Property The benefits of fair competition
- EHS Governance
- Misinformation
- Programs & Policies
- Grants Support for independent research
- Political Partnership Supporting like-minded organizations
- Working with Healthcare Professionals Collaboration to improve lives
- Prescription Value & Pricing How to lower patient costs
- Privacy Principles Commitment to personal data privacy
- Ready for Cures Improving Access to Medicines
- Transparency in Grants Committed to Disclosure
- Policy Positions
- Investors
- Investors Overview Information for stockholders
- Why Invest Why to join us in our mission
- Events & Presentations Calendar of upcoming events
- Financial Reports Quarterly reports and more
- Investor News Announcements about our performance
- Stock Information Charts and data
- Shareholder Services Information on stock transactions
- Corporate Governance
- Corporate Governance Overview Gaining insight into our performance
- Board Committees & Charters Defining the corporate structure
- The Pfizer Board Policies Ensuring ethical leadership
- Corporate Governance FAQs Learn more about our approach
- Contact Our Directors Email any of our Directors
- Purpose
- History
- Careers
- Partners
- People
Smart policies to deliver cures to patients
Patients deserve access to the treatments they depend on. That’s why Pfizer and the Ready for Cures community are working to advance smart public policies that could reduce patients’ out-of-pocket costs at the pharmacy counter and improve access to treatments — without stifling scientific innovation that could lead to life-saving cures. Potential solutions to accomplish these goals include the following:
- Support AMR research: Antimicrobial resistance (AMR) among “superbugs” is a leading cause of death around the world. Stopping the spread means investing in innovation to discover groundbreaking treatments. Prevention is key to saving lives. Legislation that incentivizes innovation can help reinvigorate a robust pipeline of new treatments to stop the spread of superbugs. Learn more about AMR.
- Invest in innovative technologies like gene therapy. Gene therapy could allow patients to live without the need for ongoing treatments or the burden of daily disease management. Investments in innovative treatments like gene therapy can help people thrive in every stage of life. Learn more about gene therapy.
- Ensure patients receive the savings they deserve: In the current broken system, insurers and pharmacy benefit managers negotiate billions of dollars in rebates and discounts from pharmaceutical companies. Instead of passing those rebates on to patients, middlemen keep these savings. And it’s only getting worse: Data reveals that insurers and PBMs are siphoning off more profits than ever before. Get the facts and learn how to help patients access healthcare savings.
- Increase the use of biosimilars: Biosimilars are FDA-approved and often offer a lower-cost alternative to biologic therapies that treat challenging diseases like cancer, diabetes, and rheumatoid arthritis. Biosimilars give patients a safe and often lower cost option than their originator biologics. Learn more about biosimilars.
Join the Ready for Cures community to receive updates on how you can help reduce out-of-pocket costs for patients and protect scientific innovation.
